SMIM27: A Potential Drug Target and Biomarker (G100129250)

Target Name: SMIM27

NCBI ID: G100129250

SMIM27

SMIM27: A Potential Drug Target and Biomarker

Spermidine-modified inositol (SMIM)27 is a novel sugar molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and psychiatric disorders. SMIM27 is a modified form of inositol, which is a sugar molecule that is found in various cell types throughout the body. It has been shown to play a crucial role in various cellular processes, including intracellular signaling, metabolism, and neurotransmission.

SMIM27 has been shown to interact with several protein molecules, including the protein known as SMIM28, which is a key regulator of the insulin/IGF-1 signaling pathway. This interaction between SMIM27 and SMIM28 has led to the hypothesis that SMIM27 may be a drug target for diseases that are characterized by insulin/IGF-1 signaling pathway dysfunction.

One of the unique features of SMIM27 is its ability to cross the blood-brain barrier (BBB), which is a barrier that separates the brain from the bloodstream. This has led to the interest in SMIM27 as a potential therapeutic agent for neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

SMIM27 has also been shown to interact with the protein known as TrkB, which is a key regulator of the T-cell receptor signaling pathway. This interaction between SMIM27 and TrkB has led to the hypothesis that SMIM27 may be a drug target for diseases that are characterized by T-cell receptor signaling pathway dysfunction.

In addition to its potential drug target properties, SMIM27 has also been shown to be a potential biomarker for various diseases. For example, SMIM27 has been shown to be elevated in the blood of individuals with Alzheimer's disease, and this increase in SMIM27 levels has been associated with an increased risk of developing Alzheimer's disease. Similarly, SMIM27 has been shown to be elevated in the urine of individuals with Parkinson's disease, and this increase in SMIM27 levels has been associated with an increased risk of developing Parkinson's disease.

SMIM27 has also been shown to be a potential therapeutic agent for various psychiatric disorders, including depression and anxiety. For example, SMIM27 has been shown to be elevated in the blood of individuals with major depressive disorder (MDD), and this increase in SMIM27 levels has been associated with an increased risk of developing MDD. Similarly, SMIM27 has been shown to be elevated in the urine of individuals with anxiety disorder, and this increase in SMIM27 levels has been associated with an increased risk of developing anxiety disorder.

In conclusion, SMIM27 is a novel sugar molecule that has been shown to interact with several protein molecules, including SMIM28 and TrkB. These interactions have led to the hypothesis that SMIM27 may be a drug target for diseases characterized by insulin/IGF-1 signaling pathway dysfunction and T-cell receptor signaling pathway dysfunction. In addition to its potential drug target and biomarker properties, SMIM27 has also been shown to be a potential therapeutic agent for various psychiatric disorders. Further research is needed to confirm these findings and to determine the full scope of SMIM27's potential as a drug target and biomarker.

Protein Name: Small Integral Membrane Protein 27

The "SMIM27 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMIM27 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets